Ark Invest purchased 37,340 shares of Pacific Biosciences of California, a renowned name in the field of genomics through ARKK and ARKG.

Source: https://www.benzinga.com/23/10/35153614/cathie-wood-goes-shopping-for-stock-of-jack-dorseys-block-ark-invest-bolsters-portfolio-with-archer

Barclays began coverage on Pacific Biosciences of California in a research note on Wednesday, May 10th.

Source: https://www.etfdailynews.com/2023/08/29/guggenheim-capital-llc-cuts-position-in-pacific-biosciences-of-california-inc-nasdaqpacb/

Equities analysts predict that Pacific Biosciences of California, Inc. will post -1.25 EPS for the current fiscal year.

Source: https://www.dailypolitical.com/2023/05/19/michele-farmer-sells-5165-shares-of-pacific-biosciences-of-california-inc-nasdaqpacb-stock.html

Finally, Canaccord Genuity Group dropped their target price on shares of Pacific Biosciences of California from $17.00 to $15.00 and set a “buy” rating on the stock in a research report on Tuesday, October 31st.

Source: https://www.americanbankingnews.com/2023/11/12/lpl-financial-llc-sells-5557-shares-of-pacific-biosciences-of-california-inc-nasdaqpacb.html

Finally, Cantor Fitzgerald boosted their target price on shares of Pacific Biosciences of California from $12.00 to $13.00 in a report on Wednesday, May 3rd.

Source: https://www.americanbankingnews.com/2023/05/27/banque-cantonale-vaudoise-acquires-shares-of-36290-pacific-biosciences-of-california-inc-nasdaqpacb.html